Karp Judith E相关文献与解析，生知库 | 链接生命科学的每一步

日期影响因子

Ethics and Clinical Research: Improving Transparency and Informed Consent in Phase I Oncology Trials

伦理与临床研究：提高I期肿瘤临床试验的透明度和知情同意率

期刊:Journal of Clinical Oncology

影响因子:41.9

doi:10.1200/JCO.22.01736

Frankel, Paul H; Groshen, Susan; Beumer, Jan H; Cleveland, Laura; Kim, Edward S; Karp, Judith E

发表日期：2023

文献求助收藏

Prognostic impact of secondary versus de novo ontogeny in acute myeloid leukemia is accounted for by the European LeukemiaNet 2022 risk classification

欧洲白血病网络2022风险分类考虑了继发性与原发性急性髓系白血病的预后影响。

期刊:Leukemia

影响因子:13.4

doi:10.1038/s41375-023-01985-y

Hochman, Michael J; Othus, Megan; Hasserjian, Robert P; Ambinder, Alex; Brunner, Andrew; Percival, Mary-Elizabeth M; Hourigan, Christopher S; Swords, Ronan; DeZern, Amy E; Estey, Elihu H; Karp, Judith E

发表日期：2023

文献求助收藏

The spectrum of genetic mutations in myelodysplastic syndrome: Should we update prognostication?

骨髓增生异常综合征的基因突变谱：我们是否应该更新预后评估？

影响因子:1.2

doi:10.1002/jha2.317

Cook, Michael R; Karp, Judith E; Lai, Catherine

发表日期：2022

文献求助收藏

Phase 1 study of the histone deacetylase inhibitor entinostat plus clofarabine for poor-risk Philadelphia chromosome-negative (newly diagnosed older adults or adults with relapsed refractory disease) acute lymphoblastic leukemia or biphenotypic leukemia

一项针对预后不良的费城染色体阴性（新诊断的老年患者或复发难治性疾病成人患者）急性淋巴细胞白血病或双表型白血病的I期研究，评估组蛋白去乙酰化酶抑制剂恩替诺特联合氯法拉滨的疗效。

期刊:Leukemia Research

影响因子:2.2

doi:10.1016/j.leukres.2021.106707

Carraway, Hetty E; Sawalha, Yazeed; Gojo, Ivana; Lee, Min-Jung; Lee, Sunmin; Tomita, Yusuke; Yuno, Akira; Greer, Jackie; Smith, B Douglas; Pratz, Keith W; Levis, Mark J; Gore, Steven D; Ghosh, Nilanjan; Dezern, Amy; Blackford, Amanda L; Baer, Maria R; Gore, Lia; Piekarz, Richard; Trepel, Jane B; Karp, Judith E

细胞生物学

发表日期：2021

文献求助收藏

A randomized trial of three novel regimens for recurrent acute myeloid leukemia demonstrates the continuing challenge of treating this difficult disease

一项针对三种新型复发性急性髓系白血病治疗方案的随机试验表明，治疗这种棘手疾病仍然面临挑战。

期刊:American Journal of Hematology

影响因子:9.9

doi:10.1002/ajh.25333

Litzow, Mark R; Wang, Xin V; Carroll, Martin P; Karp, Judith E; Ketterling, Rhett P; Zhang, Yanming; Kaufmann, Scott H; Lazarus, Hillard M; Luger, Selina M; Paietta, Elisabeth M; Pratz, Keith W; Tun, Han Win; Altman, Jessica K; Broun, Edward R; Rybka, Witold B; Rowe, Jacob M; Tallman, Martin S

发表日期：2019

文献求助收藏

Population pharmacokinetics and exposure-response assessment of veliparib co-administered with temozolomide in patients with myeloid leukemias

在髓系白血病患者中，维利帕尼与替莫唑胺联合用药的群体药代动力学和暴露-反应评估

期刊:Cancer Chemotherapy and Pharmacology

影响因子:2.3

doi:10.1007/s00280-018-3731-4

Singh, Renu; Mehrotra, Shailly; Gopalakrishnan, Mathangi; Gojo, Ivana; Karp, Judith E; Greer, Jacqueline M; Chen, Alice; Piekarz, Richard; Kiesel, Brian F; Gobburu, Jogarao; Rudek, Michelle A; Beumer, Jan H

发表日期：2019

文献求助收藏

Final results of a randomized multicenter phase II study of alvocidib, cytarabine, and mitoxantrone versus cytarabine and daunorubicin (7 + 3) in newly diagnosed high-risk acute myeloid leukemia (AML)

一项随机多中心 II 期研究的最终结果，比较了阿洛西地、阿糖胞苷和米托蒽醌与阿糖胞苷和柔红霉素 (7 + 3) 治疗新诊断的高危急性髓系白血病 (AML) 的疗效。

期刊:Leukemia Research

影响因子:2.2

doi:10.1016/j.leukres.2018.08.005

Zeidner, Joshua F; Foster, Matthew C; Blackford, Amanda L; Litzow, Mark R; Morris, Lawrence E; Strickland, Stephen A; Lancet, Jeffrey E; Bose, Prithviraj; Levy, M Yair; Tibes, Raoul; Gojo, Ivana; Gocke, Christopher D; Rosner, Gary L; Little, Richard F; Wright, John J; Doyle, L Austin; Smith, B Douglas; Karp, Judith E

发表日期：2018

文献求助收藏

A Phase 1 Study of the PARP Inhibitor Veliparib in Combination with Temozolomide in Acute Myeloid Leukemia.

PARP抑制剂Veliparib联合替莫唑胺治疗急性髓系白血病的I期研究

期刊:Clinical Cancer Research

影响因子:10.2

doi:10.1158/1078-0432.CCR-16-0984

Gojo Ivana, Beumer Jan H, Pratz Keith W, McDevitt Michael A, Baer Maria R, Blackford Amanda L, Smith B Douglas, Gore Steven D, Carraway Hetty E, Showel Margaret M, Levis Mark J, Dezern Amy E, Gladstone Douglas E, Ji Jiuping Jay, Wang Lihua, Kinders Robert J, Pouquet Marie, Ali-Walbi Ismail, Rudek Michelle A, Poh Weijie, Herman James G, Karnitz Larry M, Kaufmann Scott H, Chen Alice, Karp Judith E

发表日期：2017

文献求助收藏

Randomized phase II trial of cytosine arabinoside with and without the CHK1 inhibitor MK-8776 in relapsed and refractory acute myeloid leukemia

一项随机II期临床试验，比较阿糖胞苷联合或不联合CHK1抑制剂MK-8776治疗复发难治性急性髓系白血病的疗效。

期刊:Leukemia Research

影响因子:2.2

doi:10.1016/j.leukres.2017.09.005

Webster, Jonathan A; Tibes, Raoul; Morris, Larry; Blackford, Amanda L; Litzow, Mark; Patnaik, Mrinal; Rosner, Gary L; Gojo, Ivana; Kinders, Robert; Wang, Lihua; Doyle, L Austin; Huntoon, Catherine J; Karnitz, Larry M; Kaufmann, Scott H; Karp, Judith E; Smith, B Douglas

发表日期：2017

文献求助收藏

Timed sequential therapy for acute myelogenous leukemia: Results of a retrospective study of 301 patients and review of the literature

急性髓系白血病的定时序贯治疗：一项纳入301例患者的回顾性研究结果及文献综述

期刊:Leukemia Research

影响因子:2.2

doi:10.1016/j.leukres.2017.08.009

Norsworthy, Kelly J; DeZern, Amy E; Tsai, Hua-Ling; Hand, Wesley A; Varadhan, Ravi; Gore, Steven D; Gojo, Ivana; Pratz, Keith; Carraway, Hetty E; Showel, Margaret; McDevitt, Michael A; Gladstone, Douglas; Ghiaur, Gabriel; Prince, Gabrielle; Seung, Amy H; Benani, Dina; Levis, Mark J; Karp, Judith E; Smith, B Douglas

发表日期：2017

文献求助收藏